Among NSCLC patients that were treated with anti-PD1 (nivolumab), clinical benefit (complete response, partial response, plus stable disease), and longer OS were more frequently achieved in NSCLC patients with low plasma sPD-L1 levels than in those with high levels (>3.357 ng/mL) [91]. The gene discussed is HOXD13; the disease is non-small cell lung carcinoma.